Medspa M&A & Consolidator Tracker: Who's Buying

The PE-backed platforms dominating medspa roll-ups include MedSpa Partners, Empower Aesthetics, Alpha Aesthetics Partners, Princeton Medspa Partners, and Advanced MedAesthetic Partners, among others. Each operates under a similar model: acquire a controlling stake in a single-location or small-group practice, retain the founder/operator in a management role (often with earnout provisions), and then layer on additional acquisitions in the same or adjacent markets to build a regional or national footprint. These platforms typically raise capital from mid-market PE firms or family offices, then use that capital plus leverage to fund acquisitions. The platforms themselves become acquisition targets for larger PE firms or strategic buyers seeking scale. This creates a two-tier market: platform-level deals (where a PE firm acquires a platform that already owns multiple practices) and practice-level deals (where a platform acquires individual practices).

Acquisition multiples for aesthetic practices have historically ranged from 3.5x to 5.5x EBITDA, depending on practice size, revenue stability, provider tenure, and geographic market. Larger, multi-location platforms with strong recurring revenue (high percentage of existing-patient treatments and membership programs) command the higher end. Recent market signals suggest consolidators remain active despite broader PE market headwinds; however, multiples have compressed slightly as interest rates remain elevated and buyer hurdle rates have risen. Earnout structures are standard, typically representing 20–40% of total consideration and tied to revenue retention, patient acquisition, or EBITDA targets over 1–3 years post-close. Founders who stay on as medical directors or operators often negotiate retention bonuses and equity rollover (a small equity stake in the platform itself), aligning incentives but also locking in continued involvement.

Buyers prioritize practices with strong unit economics: high gross margins (typically 65–75% after cost of goods sold), recurring patient bases, established provider relationships, and minimal lease or real-estate encumbrances. Practices with diversified revenue streams—toxin, filler, energy devices, skincare—are more attractive than single-modality shops. Consolidators also value practices in high-density markets (major metros, affluent suburbs) where they can achieve multi-unit scale and leverage shared back-office, marketing, and supply-chain functions. Conversely, practices in secondary markets, those dependent on a single provider, or those with high customer-acquisition costs and low retention are less attractive. Regulatory compliance and clean licensing records are table stakes; any history of scope-of-practice violations, board complaints, or off-label marketing red-flags will tank a deal or significantly reduce valuation.

One underappreciated benefit of consolidation is negotiating power with manufacturers and distributors. A platform owning 5–10 practices can aggregate toxin and filler volume to unlock better rebate tiers on programs like Alle (Allergan), Aspire (Galderma), and Evolus Rewards. A single independent practice buying 100 units of Botox per month may qualify for standard rebates; a platform buying 500+ units across multiple locations can negotiate volume discounts, co-op marketing funds, and exclusive territory arrangements. This cost advantage flows directly to EBITDA and makes the platform more attractive to the next-tier buyer. Independent practices, conversely, often pay list or near-list prices and miss out on these economies. This dynamic has also prompted some independent practices to form informal buying cooperatives or join group purchasing organizations (GPOs), though these lack the operational integration and capital backing of true consolidators.

Owners considering an exit should monitor several signals: (1) consolidator fundraising activity—when platforms raise new capital, they typically deploy it within 12–24 months, signaling an active M&A window; (2) public-company earnings calls—larger PE sponsors and strategic acquirers (e.g., Allergan Aesthetics, Galderma, InMode) often signal aesthetic-practice acquisition interest in investor updates; (3) comparable transactions—tracking announced deals (even if terms are not fully disclosed) provides a sense of market appetite and valuation ranges; (4) interest-rate environment—lower rates and tighter PE fund deployment timelines favor seller-friendly terms. The current environment (mid-2026) shows consolidators remain active despite macro uncertainty, but multiples are unlikely to expand significantly without a material improvement in cost of capital or a major shift in aesthetic-procedure demand.

Before engaging with a consolidator or broker, ensure your practice is acquisition-ready: clean financials (3 years of audited or reviewed tax returns and P&Ls), documented patient acquisition costs and lifetime value, provider employment agreements with non-competes, and a clear picture of recurring vs. transactional revenue. Understand your practice's true EBITDA (add back owner compensation, one-time costs, and non-recurring items) and be realistic about growth assumptions in earnout negotiations. Have a tax advisor and M&A attorney review any term sheet before signing; earnout disputes are common, and the devil is in the definition of EBITDA and revenue retention. Finally, recognize that a consolidator acquisition is not a full exit—most deals involve founder retention and earnout periods of 2–3 years, meaning you remain operationally involved and financially exposed to post-close performance. If you want a clean break, expect a lower multiple or a smaller cash-at-close component.

Stay informed by monitoring SEC filings (8-K and 10-Q disclosures from public PE sponsors and strategic acquirers), industry publications (Dermatology Times, Aesthetic Surgery Journal), and trade conferences (American Academy of Dermatology, American Society of Plastic Surgeons). Broker reports and market surveys from firms like Mergermarket and PitchBook provide deal-flow data, though access is often behind paywalls. Peer networks and local practice owner groups are invaluable for anecdotal intelligence on recent deals and buyer appetite in your market. Finally, maintain relationships with your manufacturer reps and group purchasing organizations; they often have early sight lines into consolidator activity and can provide informal guidance on market trends and valuation benchmarks.

Consolidation is reshaping the aesthetic-practice landscape, but it is not inevitable. Many successful practices remain independent by focusing on operational excellence, strong provider retention, and direct-to-consumer marketing. The trade-off is clear: independence preserves autonomy and upside but forgoes economies of scale, manufacturer leverage, and the capital to fund growth or weather downturns. Consolidators offer capital, operational support, and a clear exit path, but at the cost of founder control and a portion of future upside. Neither path is universally superior; the right choice depends on your stage, ambitions, and personal priorities. Understanding the consolidator landscape simply ensures you make that choice from a position of knowledge, not necessity.